Deferasirox-d₄

Cat. No.: HY-17359S: FAQs
Data Sheet Handling Instructions

Molarity Calculator

Deferasirox-d₄ is the deuterium labeled Deferasirox. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload[1][2][3].

For research use only. We do not sell to patients.

Deferasirox-d<sub>4</sub> Chemical Structure

Deferasirox-d₄ Chemical Structure

CAS No. : 1133425-75-8

Size	Price	Stock	Quantity
1 mg	USD 660	Get quote 3 - 4 weeks 4 - 5 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
5 mg		Get quote
10 mg		Get quote

Synthetic products have potential research and development risk.

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Deferasirox-d₄:

Deferasirox In-stock

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description	Deferasirox-d₄ is the deuterium labeled Deferasirox. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload[1][2][3].
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Deferasirox-d₄ Related Antibodies
Molecular Weight	377.39
Formula	C₂₁H₁₁D₄N₃O₄
CAS No.	1133425-75-8
Unlabeled CAS	201530-41-8
SMILES	OC1=C(C=CC=C1)C2=NC(C3=C(C=CC=C3)O)=NN2C4=C([2H])C([2H])=C(C([2H])=C4[2H])C(O)=O
Shipping	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation	Data Sheet (273 KB) Handling Instructions (2659 KB)
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief] [2]. Sobbe A, et al. Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox. J Gastroenterol Hepatol. 2015 Mar;30(3):638-45. [Content Brief] [3]. Kim JL, et al. The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targetingcaspase. Acta Haematol. 2011;126(4):241-5. [Content Brief] [4]. Lee DH, et al. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status. Exp Hematol. 2013 Jun;41(6):539-46. [Content Brief]